Skip to main content
. 2022 Mar 28;139(23):3376–3386. doi: 10.1182/blood.2021013733

Figure 3.

Figure 3

Long-term survival in patients with R/R B-ALL with CNSL after CAR T-cell therapy. (A) The cumulative incidence of BM relapse and CNS relapse in patients achieving remission in terms of BM (n = 42) or CNS (n = 41) disease. Event of interest was defined as any pattern of relapse occurring by the cutoff day, and nonrelapse mortality and subsequent allo-HSCT were considered competing risks. Patients who did not experience relapse at last follow-up were censored. (B-F) OS analysis (B) and EFS analysis (C); EFS analysis according to CNS status before CAR T-cell infusion (D); and OS analysis (E) and EFS analysis (F) according to Ph status. The probabilities of OS and EFS were estimated by means of the Kaplan-Meier method and were compared using the log-rank test.